Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · IEX Real-Time Price · USD
3.100
-0.090 (-2.82%)
Apr 25, 2024, 11:02 AM EDT - Market open
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 8.50, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 174.19% from the current stock price of 3.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for GANX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +190.32% | Apr 25, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 | Buy | Maintains | $9 | +190.32% | Apr 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +190.32% | Apr 1, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +93.55% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +190.32% | Dec 4, 2023 |
Financial Forecast
Revenue This Year
1.17M
from 55.18K
Increased by 2,025.77%
Revenue Next Year
408.00K
from 1.17M
Decreased by -65.22%
EPS This Year
-1.21
from -1.71
EPS Next Year
-1.16
from -1.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.1M | 420,000 | 236,250 | 36.0M | n/a |
| Avg | 1.2M | 408,000 | 114,750 | 17.5M | n/a |
| Low | 294,000 | 392,000 | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3,705.7% | -64.2% | -42.1% | 31,269.9% | - |
| Avg | 2,025.8% | -65.2% | -71.9% | 15,136.6% | - |
| Low | 432.8% | -66.6% | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.98 | -0.91 | -1.75 | -0.51 |
| Avg | -1.21 | -1.16 | -1.70 | -0.50 |
| Low | -1.57 | -1.56 | -1.64 | -0.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.